A German biopharmaceutical company says it intends to launch two mid-stage clinical trials next year to test its oral treatment candidate izicopan — a next-generation therapy that developer Inflarx says may offer an “improved safety profile” and “more convenient dosing” — in people with ANCA-associated vasculitis (AAV).
News
People with ANCA-associated vasculitis (AAV) who have pulmonary nodules ( rounded masses of tissue in the lungs) at diagnosis are more likely to experience relapses involving these nodules than those without, a study found. Fewer nodules with a hollow center, a smaller nodule cavity, and a lower ratio of…
Izicopan, InflaRx’s experimental oral therapy for ANCA-associated vasculitis (AAV), was shown to reduce kidney damage in two different animal models of kidney injury. That’s according to data presented in a poster at the American Society of Nephrology’s Kidney Week 2026, held Oct. 21-25 in Denver. The poster was…
Older age and poorer kidney function at diagnosis are each linked to a higher risk of death among people with ANCA-associated vasculitis (AAV), a real-world study in Turkey found. These two factors, as well as lung involvement and heart involvement, were found to be independent predictors of death within…
Fewer than one-quarter of people with ANCA-associated vasculitis (AAV) in the U.S. who are taking strong immunosuppressive drugs to keep AAV symptoms in check receive recommended preventive care to protect against potentially severe fungal lung infections, according to a U.S. study of Medicare insurance claims. That’s despite clear data…
Blinatumomab, a blood cancer treatment, improved kidney function in two people newly diagnosed with ANCA-associated vasculitis (AAV) and rapidly progressive glomerulonephritis (RPGN), or inflammation in the kidney’s filtering units, a study shows. The therapy is designed to promote an interaction between immune T-cells, which can kill other cells, and…
Adults with ANCA-associated vasculitis (AAV) who experience a relapse after stopping maintenance therapy show a distinct gene activity signature in their blood compared with those who are newly diagnosed or in remission, a study shows. The results point specifically to genes that control the release of pro-inflammatory molecules from…
Alentis Therapeutics and CSL are joining forces to develop and commercialize lixudebart, an infusion treatment candidate for people with ANCA-associated vasculitis (AAV) who also have rapidly progressive glomerulonephritis (RPGN), a severe form of kidney damage. The partnership joins Alentis‘ expertise as lixudebart’s original developer with CSL‘s…
Orbital MRI scans, which assess the tissues surrounding the eyes, may help differentiate granulomatosis with polyangiitis (GPA) from other conditions affecting the eye socket, a new study demonstrates. “From a clinical perspective, [the identified] imaging features can help differentiate GPA from its mimics, guide timely biopsy decisions, and support…
A type of artificial intelligence (AI) identified three main forms of eosinophilic granulomatosis with polyangiitis (EGPA), each characterized by distinct biological changes and disease manifestations, according to a new study. Findings suggest that the three groups may also differ in how patients respond to treatment. Although further work…
Recent Posts
- Making the argument (again) that we should scrap ‘lived experience’
- Developer intends to launch 2 trials next year to test oral vasculitis treatment
- To improve care, doctors and patients must be in it together
- Lung nodules at AAV diagnosis may point to more relapses
- Experimental AAV treatment reduces kidney damage in animal models